← FDA DRUG APPROVALS

FDA NDA · NDA011971

ORETIC

Sponsor: ABBVIE

APPLICATION
NDA011971
TYPE
NDA
ORIGINAL APPROVAL
1959-07-06
LATEST ACTION
1998-04-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

ORETICDiscontinued
HYDROCHLOROTHIAZIDE 25MG · TABLET · ORAL
ORETICDiscontinued
HYDROCHLOROTHIAZIDE 50MG · TABLET · ORAL

Approval history

1998-04-16Manufacturing (CMC) · Supplement 27 · standardAP
1991-09-13Labeling · Supplement 21 · standardAP
1985-07-15Manufacturing (CMC) · Supplement 25 · standardAP
1983-12-15Manufacturing (CMC) · Supplement 24 · standardAP
1982-06-11Manufacturing (CMC) · Supplement 22 · standardAP
1982-05-14Manufacturing (CMC) · Supplement 23 · standardAP
1976-06-29Manufacturing (CMC) · Supplement 16 · standardAP
1976-02-03Labeling · Supplement 15 · standardAP
1975-03-03Labeling · Supplement 12 · standardAP
1959-07-06Type 5 - New Formulation or New Manufacturer · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →